Aarti Drugs Ltd Q4 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/jy4t558yf0vfm1m6qc38yww8.pdf

Key Takeaways


Volume Growth & Revenue Outlook

Adhish Patil: "The first target would be to maintain such volumes for -- as far as our normal API markets are concerned. And the addition of new production lines, the new products itself, that will give a further impetus in growth -- overall growth of the company."

Margin Trajectory & Sustainability

Adhish Patil: "14% to 15% is the stable guidance what we are giving here."

USFDA Clearance & Regulated-Market Opportunity

Adhish Patil: "This clears out the stigma among the European buyers. We have a very big potential for selling our APIs to European market, which was withheld because of this import alert issue."

Capacity Expansion & Capex


Formulation & Specialty Chemicals


Competitive Positioning & External Tailwinds

Adhish Patil: "if Chinese products have relatively more tariff than India, let's just say even 10%. So that gives us clearly 10% advantage for the pricing of our products. So we become more competitive by 10%, which is quite a big margin, frankly speaking, for Indian manufacturers."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth10–15% overall, 20–25% for formulationsFY26
Volume baseMaintain Q4 FY25 volumes in normal API marketsFY26
EBITDA margin14–15% standalone and consolidatedFY26 (stable)
Tarapur productionOver 700 tons/monthJune 2025
Tarapur cumulative capacity~1,600 tons/monthEnd FY26
Capex₹150–200 croresFY26
Revenue milestoneCross ₹3,000 crores, then try for ₹3,500 croresFY27
Power and fuel savings₹10–15 crores benefitFY26
Power and fuel savings₹25–30 crores benefitFY27 onward
Formulation oncology approvalsAt least 2 approvals in regulated marketsH2 FY26
Specialty chemicals sales₹200–250 croresWithin 2 years

Key Metrics

MetricQ4 FY25
Revenue₹679 cr, +9% YoY
Standalone revenue₹624 cr
EBITDA margin14%, improved from prior quarters
Standalone EBITDA margin~14.5%
PAT₹63 cr, +33% YoY
PAT margin9.2%
Volume growth~15% overall; export volumes up late 20% YoY
Rate varianceminus 4% to 5% YoY; QoQ stabilized at 1% to 2%
Gross margin (FY25 full year)35.8%, improved over 200 bps YoY
FY25 full year EBITDA margin12.6%
FY25 full year revenue5% YoY decline
FY25 API business revenue4% YoY decline
FY25 capex incurred₹177 cr
FY26 capex guidance₹150 cr to ₹200 cr
Tarapur Greenfield targetover 700 tons/month by June 2025; ~1,600 tons/month by end FY26
Saykha and Tarapur Greenfield capex₹180 cr to ₹200 cr each, Phase 1 only
North American exports11% of sales, includes Canada, US, Mexico
USFDA clearance gestation period12 to 24 months for sales impact
Specialty chemicals sales (FY25)~₹130 cr; target ₹200 cr to ₹250 cr in 2 years
Formulation revenue growth target (FY26)20% to 25%
Consolidated EBITDA margin target (FY26)14% to 15%
Revenue targetcross ₹3,000 cr on immediate basis, then ₹3,500 cr; previous ₹4,000 cr target revised down
Overall revenue growth expectation (FY26)10% to 15%
Power and fuel savings potential₹25 cr to ₹30 cr full-year; ₹10 cr to ₹15 cr expected in FY26
Metronidazole production capacityincreased from 245 tons to 330 tons/month
Debtor cycletypically ~90 days
Investment in Prozeal Green Power₹8.05 cr for 26.25% equity and CCDs in 24.4 MW peak solar SPV
FY26 first half expected rate variance3% to 4% negative; second half no negative rate variance expected